그래서 섯다 룰이 대체 뭔데? - 테이블탑 시뮬레이터 게시자: 숄 2년 전 1시간 7분 조회수 19,045회
OSAKA, JAPAN--( / ) March 30, 2017 -- Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that data from a 6-month interim analysis* of the ongoing DEN-204 trial of its live-attenuated tetravalent dengue vaccine candidate, TAK-003 (also referred to as TDV), have been published in The Lancet Infectious Diseases.
The trial investigated the safety and immunogenicity of TAK-003 in 1,794 participants ages two through 17 living in dengue-endemic areas (the Dominican Republic, Panama and the Philippines). At the time of the analysis, participants had either received one dose of TAK-003, two doses of TAK-003 administered three months apart, or a placebo.
The published data showed that TAK-003 elicited a broad antibody response against all four dengue virus types (called serotypes), regardless of previous exposure to the dengue virus. The increased presence of antibodies in the blood against the four serotypes (seropositivity) ranged between 87-100% by Month 1 and was sustained at Month 6 (85-100%) in both the one-dose and two-dose groups. This analysis also showed that, in participants who were not previously exposed to dengue infection (seronegative) before vaccination, seropositivity rates against dengue virus types 3 and 4 were improved after a second dose of vaccine. For this reason, a two-dose regimen, administered three months apart, was selected for Takeda’s ongoing global pivotal Phase 3 efficacy trial.
This analysis also showed that TAK-003 was safe and well-tolerated in children and adolescents in terms of solicited local reactions and systemic adverse events; no vaccine-related serious adverse events (SAEs) occurred, and the expected immunological responses to the vaccine and associated signs and symptoms (reactogenicity) was limited. The number of adverse events reported were similar or lower than those reported for other live attenuated vaccines, and the safety profile was consistent with that observed in earlier Phase 1 and 2 studies of the vaccine candidate.
Dengue fever is a painful, debilitating mosquito-borne disease caused by any one of four closely related virus serotypes. Forty percent of the world lives under the threat of dengue, which can affect people of all ages and is a leading cause of serious illness and death among children throughout the world.[4,5]
“The levels of immunogenicity induced by TAK-003 against all four dengue serotypes, even in seronegative participants, are encouraging because seropositivity after vaccination may be an important measure of vaccine performance,” said Xavier Saez-Llorens, M.D., primary author of The Lancet Infectious Diseases publication and Head of Infectious Diseases and Director of Clinical Research at the Panama Children’s Hospital. “Infection with one dengue serotype makes subsequent infection with a different serotype a major risk factor for severe disease, hence the need for a safe and effective vaccine that simultaneously protects against all four serotypes. The durability of these antibody responses and the contribution of cell-mediated immune responses to disease protection warrant further study.”
“These and other Phase 1 and Phase 2 safety and immunogenicity data support continued development of this important vaccine candidate,”[1,7,8] said Derek Wallace, M.B.B.S., Global Dengue Program Head at Takeda. “We look forward to ongoing studies, which will assess the candidate vaccine’s ability to provide protection against all four dengue serotypes in recipients of all ages, whether or not they have been previously exposed to dengue.”
In September 2016, Takeda initiated its pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES). The randomized, double-blind, placebo-controlled, multi-center trial is designed to investigate the efficacy, safety and immunogenicity of Takeda’s dengue vaccine candidate, administered in two doses, three months apart, in dengue-endemic countries in Latin America and Asia. Evaluation of the trial’s primary endpoint, vaccine protection against virologically-confirmed dengue of any severity caused by any serotype regardless of previous exposure, is expected in 2018. Secondary endpoints include vaccine efficacy in preventing dengue induced by each serotype, vaccine efficacy in preventing dengue caused by any serotype regardless of participants’ baseline status, vaccine efficacy in preventing hospitalization due to dengue, and vaccine efficacy in preventing severe dengue induced by any serotype.
*An interim data analysis is a pre-planned evaluation of data from an ongoing trial before final data collection.
About the Phase 2 DEN-204 Study
The Phase 2 DEN-204 study is a randomized, double-blind, placebo-controlled, multi-center trial designed to assess the safety and immunogenicity of either a one- or two-dose schedule of TAK-003 in 1,794 healthy participants living in dengue-endemic areas (the Dominican Republic, Panama and the Philippines). Participants were ages two through 17 and were randomized to one of four groups, two of which received a one-dose vaccine schedule, one of which received a two-dose vaccine schedule administered three months apart, and one which received placebo, by the 6 month interim analysis timepoint. The primary endpoint of this interim analysis was geometric mean titers (GMTs) of neutralizing antibodies (an indicator of immune response) to the four dengue virus serotypes (DENV-1-4) in the per protocol immunogenicity subset (PPS), a group of participants who had no major protocol violations and for whom valid pre- and post-dosing blood samples were available and immunogenicity was evaluated at months one, three, and six. Secondary endpoints included occurrence of serious adverse events (SAEs), seropositivity rates (percentage of participants who developed antibodies), and adverse events (AEs) in the immunogenicity subset.
About Takeda’s Dengue Vaccine Candidate (TAK-003)
Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus (DENV-2), which provides the genetic ‘backbone’ for all four vaccine viruses. Takeda’s dengue vaccine is being developed to support the protection of populations and individuals at risk for dengue across geographies whether or not they have had previous exposure to dengue virus, including children and adults, travelers and those living in endemic areas.
Phase 1 data has been published in the Journal of Infectious Diseases, Lancet Infectious Diseases and Vaccine. Interim results of DEN-203, a Phase 2, placebo-controlled, multi-center, age-descending trial, were presented during the American Society of Tropical Medicine and Hygiene (ASTMH) meeting in October 2015. Interim results of DEN-204 were also presented during the 5th Annual Pan-American Dengue Research Network Meeting in May 2016 and ASTMH in November 2016.[10,11]
Takeda’s Commitment to Vaccines
Vaccines prevent more than two million deaths each year and have transformed global public health. For 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, Zika, norovirus and polio. Our team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit
 Saez-Llorens, Tricou, et al. (2017). Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine: Interim results of a long-term phase 2, randomized, placebo-controlled pediatric trial in Asia and Latin America. Lancet Infectious Diseases. Retrieved March 2017, from (17)30166-4/fulltext?elsca1=tlxpr.
 ClinicalTrials.gov. Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children (TIDES). (2016) Retrieved May 2016, from
 World Health Organization, Vector-borne diseases dengue fact sheet. Retrieved March 2017, from
 World Health Organization (2016). Dengue and severe dengue. Retrieved May 2016, from
 Centers for Disease Control and Prevention (2014). Dengue homepage: Epidemiology. Retrieved September 2016, from
 Scitable by Nature Education. Host Response to the Dengue Virus. Retrieved March 2017, from
 Osorio, J. E., Velez, I. D., Thomson, et al. (2014). Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infectious Diseases, 14(9), 830-838. doi:10.1016/s1473-3099(14)70811-4.
 Wallace, D. (2015). Persistence of neutralizing antibodies one year after two doses of a candidate recombinant tetravalent dengue vaccine in subjects aged from 1.5 to 45 years. Presented at 64th Annual Meeting, American Society of Tropical Medicine and Hygiene.
 Huang, C. Y.-H., Osorio, J.E., et. Al. (2013). Genetic and Phenotypic Characterization of Manufacturing Seeds for Tetravalent Dengue Vaccine (DENVax). PLoS Neglected Tropical Diseases, 7(5): e2243. doi: 10.1371/journal.pntd.0002243.
 Saez-Llorens X., et al. (2016). Phase II, double-blind, controlled trial to assess the safety and immunogenicity of different schedules of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) in healthy subjects aged between 2 and <18 years and living in dengue endemic countries in Asia and Latin America. Presented at 5th Pan-American Dengue Research Network Meeting.
 Wallace, D. (2016). Takeda’s Tetravalent Dengue Vaccine Candidate. Presented at 65th Annual Meeting, American Society of Tropical Medicine & Hygiene.
 UNICEF. Immunization Facts and Figures (2013). Retrieved September 2015, from (1).pdf.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
CHIBA, JAPAN--( / ) October 12, 2016 -- SII Semiconductor Corporation, an 듀렉스 affiliate of Seiko Instruments Inc., announced that in October it will release the S-174x Series of LDO regulators with 몰디브섯다 CHIBA,current consumption, helping to reduce the power consumption of 아이폰현금섯다 CHIBA,and IoT devices. The S-174x Series is the industry’s first 스포츠토토결과 LDO regulator 농구스페셜배당률보기 to come equipped with a power monitor output function. The series is designed for optimal use with low-voltage microcontrollers for wearable 한게임설치하기 CHIBA,and other equipment.
The 7m데이터 power monitor output function divides the 위너크림 battery voltage of the input to the 섯다 Theregulator, by half or one-third, and outputs the divided voltage for power monitoring. The power monitoring output voltage 토토365 is connected to the A/D converter of a low-voltage microcontroller, making it possible to monitor 고스톱 Thebattery voltage (input voltage of the regulator). The S-174x Series eliminates the need for external resistors used in conventional systems to divide the voltage for battery monitoring. This new series also features an ultra-low current consumption of 0.5μA, helping to reduce power consumption of wearable and IoT devices and extend battery life.
The power monitoring output is an analog output, which allows users to set multiple threshold values for battery voltage monitoring 포커 Thethe microcontroller side. This allows the user to turn off 코끼리팬티 the communication function and 텐가가격 record data logs only when the battery voltage falls to a specified level. 맞고 The 남성성기단련 the voltage drops further, the user can switch the device to standby mode and stop power consumption to prevent system malfunction.
The S-174x Series 동행복권파워볼점검 of 란제리 LDO regulators is available in ultra-small packages 섯다팁 Thethe HSNT-6 (1.2×1.2×0.4mm) and the HSNT-4 (1.0×1.0×0.4mm), which 재갈 help allow for improved thinness of the design which is 야한속옥 optimal for wearable and IoT 성잉용품 devices. The SOT-23-5 (2.8×2.9×1.3mm) package is also an 섯다족보정리 The
섯다족보표 About섯다끗계산 About 엔트리파워볼패턴 엔트리파워볼패턴 Semiconductor Corporation
SII 섹쉬팬티 Semiconductor Corporation, 넷마블섯다족보 SIIsemiconductor 섯다기술 SIIin Seiko Instruments Group, offers analog 파워볼알파고프로그램 semiconductor products such as Power Management ICs, EEPROMs, Sensors, Timer ICs, Amplifiers and ASSPs; featuring small size, low 섹순이 current consumption and high accuracy.
View source version on businesswire.com:Korea Newswire X샵 distributes your news across every PC섯다 View 여자야한속옷 channels through the industry’s largest press release 고스톱2018 Viewnetwork